CTX Flashcards

1
Q

Group in which cyclophosphamide belongs

A

Alkylating agents, nitrogen mustard analog

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Mechanism of action of ctx

A

Cell cycle non specific
Bifurcation all electrophiles
Attaches to N 7 position of guanine and causes inter stand DNA breakages

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Metabolism of ctx

A

Liver by microsomes oxidases
Cytochrome P450 enzymes
Ctx is a prodrug and forms 4 hydroxy ctx which is in equilibrium with aldophosphamide and it undergoes oxidation with aldehyde dehydrogenase to form inactive metabolites .
Aldophosphamide form active metabolite phospharamide mustard and acrolein (urotoxic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Route of ctx

A

Oral and Iv

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Distribution of ctx

A

20% of ctx protein bound , 60% of metabolites are protein bound
Distribution in brain and csf

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Elimination of ctx

A

20% urine
4% bile

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Dose reduction of ctx

A

In renal and hepatic impairment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Indications of ctx

A

Breast
NHL
Cll
Ovarian
Sts
Neuroblastoma and wilms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Dose of ctx

A

10-15 mg per kg for 10

Breast 600 mg per m2 every 3 weekly in ac regimen

NHL : 400 to 600 mg per m2 every 21 days

Oral 1 to 5 mg per kg per day every day for initial and maintence dosing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Toxicity of ctx

A

Myelosuppression dose limiting
Bladder toxicity
Nause/ vomiiting
Amenorrhea/ sterility
Cardiotoxicityincreasing with doxorubicin, trastuzumab and chest rt
Immunosuppression requiring prophylactic antivirals, fungal and antibiotics
Second malignancy
Alopecia after 2-3 weeks and hyperpigmentation of skin and nails
Pregnancy cat d
Venocuulisive disease
Potent emetogenic after 1500 mg per m2
SIADH like syndrome causing hyponatremia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Treatment for myelosuppression in ctx

A

Pancytopenia
Netutropenia specially
Stop treatment if neutrophils less than 1500 and platelets less than 50 thousand
Primary and secondary prophylaxis with g csf is needed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Urotoxicity of ctx

A

Aggressive hydration
Mesna
Check rbc in urine
Discontinue treatment with ctx if severe hemorrhagic cystitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Can you give ctx with tamoxifen and y.?

A

Increased increased risk of thromboembolic events

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Storage

A

Below 25 degree celcisum , use immediately after reconstitution

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How to reconstitute ctx

A

With normal saline or distilled water
For dilution of reconstituted solution use 5 % dextrose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How does metabolism occur and half life

A

Ctx is an enzyme inducer and induced it’s own metabolism
Half life is 2 to 8 hrs

17
Q

Emetogenic potential

A

Moderate risk at 1500 mg per m2
High risk after 1500 mg per m2

So combo of dexa odansetron and aprepitant is used

18
Q

When to administer ctx

A

Morning

19
Q

Other uses and doses

A

Multiple myeloma : 300 mg per m2 ORAL on day 1, 8,15, 22 of 28 day cycle

ALL : 1200 mg/ m2 IV on day 1 of 28 day cycle

HyperCVAD IN ALL : 300 mg per m2 IV Q12 HRS DAY 1 TO 3